NewS Archive

Sequel company Bonum emerges in wake of Roche’s Good Tx acquisition

Roche to pay $250M for Good Therapeutics and its targeted drug technology

Roche Buys IL-2 Technology From Good, Which Forms New Firm Bonum

Good Therapeutics being acquired by Roche for $250M

Bonum to continue Good work after $250M cash acquisition deal with Roche

Roche shells out $250M to acquire Good Therapeutics and its preclinical oncology program

Roche to acquire Good Therapeutics’ lead drug program for $250M, plus milestone payments

Roche pays $250 million to acquire Good Therapeutics and its preclinical cancer therapy

Good Therapeutics sells PD-1 IL-2 program to Roche for $250M and will march on with a similar name, but in Latin